反応式
[S:1]1[CH:5]=[CH:4][C:3]([CH:6]=[CH:7][CH2:8][C:9]([OH:11])=[O:10])=[CH:2]1.[Cl:12][C:13]1[CH:31]=[CH:30][C:16]2[O:17][C:18]3[CH:29]=[CH:28][CH:27]=[CH:26][C:19]=3[CH2:20][N:21]([C:22]([NH:24][NH2:25])=[O:23])[C:15]=2[CH:14]=1>>[O:11]=[C:9]([NH:25][NH:24][C:22]([N:21]1[CH2:20][C:19]2[CH:26]=[CH:27][CH:28]=[CH:29][C:18]=2[O:17][C:16]2[CH:30]=[CH:31][C:13]([Cl:12])=[CH:14][C:15]1=2)=[O:23])/[CH:8]=[CH:7]/[CH2:6][C:3]1[CH:4]=[CH:5][S:1][CH:2]=1.[O:10]=[C:9]([NH:25][NH:24][C:22]([N:21]1[CH2:20][C:19]2[CH:26]=[CH:27][CH:28]=[CH:29][C:18]=2[O:17][C:16]2[CH:30]=[CH:31][C:13]([Cl:12])=[CH:14][C:15]1=2)=[O:23])/[CH:8]=[CH:7]\[CH2:6][C:3]1[CH:4]=[CH:5][S:1][CH:2]=1参加物
4
反応物 2
生成物 2
実験手順
8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[1-oxo-4-(3-thienyl)-3E-butenyl]hydrazide (trans) (30) and 8-chlorodibenz[b,f][1,4 ]oxazepine-10(11H)-carboxylic acid, 2-[1-oxo-4-(3-thienyl)-3Z-butenyl]hydrazide (cis) (31) were prepared in the manner described in Example 7 on a 5.2 mmol scale from 4-(3-thienyl)-3-butenoic acid (29), prepared as described above in Example 29, and 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, hydrazide (1), prepared as described above in Example 1, to yield 33% trans and 14% cis products after separation by column chromatography.
後処理
- customprepared
- customprepared
- customto yield 33% trans and 14%
- customafter separation by column chromatography
出典と根拠
- ORDレコード
- ord-c45bc94649a046478db5ef1f93050175
- 出典データセット
- uspto-grants-1995_11
- 特許番号
- US05464830
関連ノート
読み込み中…